Hundreds more people with suspected kidney cancer should have a biopsy to help confirm their diagnosis sooner and treat their disease more effectively, according to new draft guidelines from NICE.

Durvalumab, also known as Imfinzi and made by AstraZeneca, is recommended in final draft guidance for adults with limited-stage small cell lung cancer (SCLC). This is where the cancer is contained in ...

In the lead-up to World Duchenne Awareness Day on Sunday 7 September, we’re pleased to announce the completion of our first assessment of an externally developed clinical guideline.

Fertility clinics should not offer unproven treatments that don't help people have babies, our independent committee has recommended in draft guidance.

Pneumonia: diagnosis and management QS110 19 January 2016 2 September 2025 Pneumonia: diagnosis and management NG250 2 September 2025 2 September 2025 Suspected acute respiratory infection in over 16s ...

There are commercial access agreements for enfortumab vedotin and pembrolizumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Access to hybrid closed loop systems will be through a 5‑year phased roll out in line with NHS England's implementation plan. For enquiries about cost-effective pricing, contact Leigh.Carr@supplychain ...

This guideline covers general principles for prescribing and managing withdrawal from opioids, benzodiazepines, gabapentinoids, Z‑drugs and antidepressants in primary and secondary care. It does not ...

This guideline covers care during labour and birth for women who need extra support because they have a medical condition or complications in their current or previous pregnancy. The guideline also ...

This guideline covers managing Crohn’s disease in children, young people and adults. It aims to reduce people’s symptoms and maintain or improve their quality of life. NICE has also produced a ...

This guidance has been updated and replaced by osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer ...